Find Clinical Trials

Back My cancer has not gone away or has come back Cancer progressed on treatment

Answer each question to find trials that best match your clinical situation. You can leave questions blank if you do not know the answer.

This search will output a list of trials for which you may be eligible based on the criteria you enter.

I want to enter information about my cancer and treatments

I want to enter information about my genetic testing (e.g, BRCA) and/or tumor testing results

I want to filter the trials based on location, phase of development, tumor genomic alteration, or drug name, category or target

Return only trials with results

Include all Phase 1 trials (i.e., dose-finding as well as expansion)

Matching Trials

For more detailed information please click on the clinical trial number and you will be taken to the clinicaltrials.gov website.
For a key to the icons and text used in the Results column, please click here.
To learn more about our trial annotation process, results assignments, and the criteria used to highlight drugs with promising results, please click here.

III

Platinum resistant ovarian cancer

Standard Chemotherapy Versus Cancer Stem Cell Assay Directed Chemotherapy in Recurrent Platinum Resistant Ovarian Cancer

CA, FL, IN, LA, OH, OK, PA, WV

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Carboplatin	Paraplatin, Novoplatinum	DNA damaging agent	Approved in Ovarian Cancer
Cisplatin	CACP, cis-DDP, cis-platinum, CDDP, Platinol, Abiplatin, Blastolem, Briplatin, Cisplatyl, Citoplatino, Citosin, Lederplatin, Metaplatin, Neoplatin, Placis, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platiran, Platistin, Platosin	DNA damaging agent	Approved in Ovarian Cancer
Docetaxel	Taxotere	Microtubule stabilizer/mitotic inhibitor	Approved in Other Cancers
Gemcitabine	Gemzar	Ribonucleotide reductase and DNA synthesis inhibitor	Approved in Ovarian Cancer
Liposomal doxorubicin	Pegylated Liposomal Doxorubicin Hydrochloride, liposomal doxorubicin, LipoDox, Evacet, Dox-SL, Doxil	Topoisomerase II inhibitor	Approved in Ovarian Cancer
Paclitaxel	Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL	Microtubule stabilizer/mitotic inhibitor	Approved in Ovarian Cancer
Topotecan	Hycamptamine, Hycamtin, TOPO	Topoisomerase I inhibitor	Approved in Ovarian Cancer

III

Platinum resistant FRalpha+ high grade serous ovarian cancer

MIRASOL: A Randomized, Open-label, Phase 3 Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression

AL, AK, AZ, CA, CO, CT, FL, GA, HI, IL, IN, KS, KY, LA, MD, MA, MI, MN, MO, MT, NV, NJ, NY, NC, OH, OK, OR, PA, RI, TN, TX, VA, WA, WV

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Mirvetuximab soravtansine	M9346A-sulfo-SPDB-DM4, IMGN853, Anti-FOLR1-mab Maytansinoid Conjugate	ADC: anti-FOLR1 + microtubule destabilizer (DM4)	Clinical Trials

III

Platinum resistant or refractory gBRCA WT high grade serous or endometrioid ovarian cancer

EPIK-O: A Phase III, Multi-center, Randomized (1:1), Open-label, Active-controlled, Study to Assess the Efficacy and Safety of Alpelisib (BYL719) in Combination With Olaparib as Compared to Single Agent Cytotoxic Chemotherapy, in Participants With no Germline BRCA Mutation Detected, Platinum-resistant or Refractory, High-grade Serous Ovarian Cancer

AZ, AR, FL, IL, MD, MA, NY, OH, SD, TN, TX

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Alpelisib	PI3K inhibitor BYL719, BYL719, phosphoinositide 3-Kinase inhibitor BYL719, Piqray	PI3K alpha inhibitor	Approved in Other Cancers
Olaparib	Lynparza, AZD2281	PARP inhibitor	Approved in Ovarian Cancer

III

Platinum resistant high grade serous ovarian cancer; no prior paclitaxel for platinum resistant disease

A Phase 3, Randomized, Double-Blind, Adaptive, Placebo/Paclitaxel-Controlled Study of AVB-S6-500 in Combination With Paclitaxel in Patients With Platinum-Resistant Recurrent Ovarian Cancer (AXLerate-OC)

AL, CA, CO, CT, FL, GA, IL, IN, KY, LA, ME, MD, MA, MI, MN, MO, MT, NV, NJ, NM, NY, NC, OH, OK, OR, PA, RI, SC, SD, TN, TX, VA, WA, WV, WI

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Batiraxcept	anti-AXL fusion protein AVB-S6-500, AVB-S6-500, AVB-500	GAS6 antagonist	Clinical Trials
Paclitaxel	Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL	Microtubule stabilizer/mitotic inhibitor	Approved in Ovarian Cancer

III

Platinum resistant ovarian cancer that must have had prior bevacizumab

An Open Label Randomized Study of Navicixizumab Plus Paclitaxel and Navicixizumab Monotherapy in Comparison to Paclitaxel Monotherapy in Patients With Platinum-Resistant Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Contact research study staff

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Navicixizumab	OMP-305B83, anti-DLL4/VEGF bispecific monoclonal antibody OMP-305B83	DLL4 and VEGF antagonist	Clinical Trials
Paclitaxel	Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL	Microtubule stabilizer/mitotic inhibitor	Approved in Ovarian Cancer

III

Platinum resistant or refractory ovarian cancer that must have had prior bevacizumab (≤5 prior therapies for platinum resistant disease)

A Phase 3, Multicenter, Open-Label, Randomized Study of Nemvaleukin Alfa in Combination With Pembrolizumab Versus Investigator's Choice Chemotherapy in Patients With Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

FL, NY

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Nemvaleukin alfa	intermediate-affinity interleukin-2 receptor agonist ALKS 4230, Nemvaleukin, ALKS4230	IL-2/IL-15R beta and gamma agonist	Clinical Trials
Pembrolizumab	Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475	Blocks PD-L1/2 inhibition of T cells	Approved in Other Cancers

III

Platinum resistant ovarian cancer; 1-2 prior systemic therapies

A Phase 3, Randomized, Double-Blind Study of Pembrolizumab Versus Placebo in Combination With Paclitaxel With or Without Bevacizumab for the Treatment of Platinum-resistant Recurrent Ovarian Cancer (KEYNOTE-B96/ENGOT-ov65)

CA, FL, GA, IN, MD, MA, NJ, NC, OH, OR, PA, TN, TX, VA

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Bevacizumab	Avastin, anti-VEGF monoclonal antibody, immunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain	VEGF antagonist	Approved in Ovarian Cancer
Paclitaxel	Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL	Microtubule stabilizer/mitotic inhibitor	Approved in Ovarian Cancer
Pembrolizumab	Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475	Blocks PD-L1/2 inhibition of T cells	Approved in Other Cancers

III

Platinum resistant high grade serous or high grade endometrioid ovarian cancer

A Phase 3 Study of Relacorilant in Combination With Nab-Paclitaxel Versus Investigator's Choice in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer

Contact research study staff

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
nab-Paclitaxel	Paclitaxel Albumin-Stabilized Nanoparticle Formula, Abraxane, ABI-007	Microtubule stabilizer/mitotic inhibitor	NCCN Guidelines for Ovarian Cancer
Relacorilant	RELA, CORT125134	GR antagonist	Clinical Trials

III

Platinum resistant or refractory ovarian cancer that must have had prior bevacizumab

A Randomized Phase 3 Study Assessing the Efficacy and Safety of Olvi-Vec Followed by Platinum-doublet Chemotherapy and Bevacizumab Compared With Platinum-doublet Chemotherapy and Bevacizumab in Women With Platinum-Resistant/Refractory Ovarian Cancer

FL

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Bevacizumab	Avastin, anti-VEGF monoclonal antibody, immunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain	VEGF antagonist	Approved in Ovarian Cancer
Carboplatin	Paraplatin, Novoplatinum	DNA damaging agent	Approved in Ovarian Cancer
Cisplatin	CACP, cis-DDP, cis-platinum, CDDP, Platinol, Abiplatin, Blastolem, Briplatin, Cisplatyl, Citoplatino, Citosin, Lederplatin, Metaplatin, Neoplatin, Placis, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platiran, Platistin, Platosin	DNA damaging agent	Approved in Ovarian Cancer
Gemcitabine	Gemzar	Ribonucleotide reductase and DNA synthesis inhibitor	Approved in Ovarian Cancer
Liposomal doxorubicin	Pegylated Liposomal Doxorubicin Hydrochloride, liposomal doxorubicin, LipoDox, Evacet, Dox-SL, Doxil	Topoisomerase II inhibitor	Approved in Ovarian Cancer
Olvimulogene nanivacirepvec	light-emitting oncolytic vaccinia virus GL-ONC1, GLV-1h68, GL-ONC1	Induces immune response and tumor cell lysis	Clinical Trials

II

Recurrent ovarian cancer

Avatar-Directed Chemotherapy in Platinum-Resistant Ovarian, Primary Peritoneal and Fallopian Tube Cancers

AZ, FL, MN

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Gemcitabine	Gemzar	Ribonucleotide reductase and DNA synthesis inhibitor	Approved in Ovarian Cancer
Liposomal doxorubicin	Pegylated Liposomal Doxorubicin Hydrochloride, liposomal doxorubicin, LipoDox, Evacet, Dox-SL, Doxil	Topoisomerase II inhibitor	Approved in Ovarian Cancer
Paclitaxel	Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL	Microtubule stabilizer/mitotic inhibitor	Approved in Ovarian Cancer
Topotecan	Hycamptamine, Hycamtin, TOPO	Topoisomerase I inhibitor	Approved in Ovarian Cancer

II

Advanced solid tumors with KRAS or NRAS mutations

An Open Label, Two-Part, Phase Ib/II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of the MEK Inhibitor Trametinib and the BCL2-Family Inhibitor Navitoclax (ABT-263) in Combination in Subjects With KRAS or NRAS Mutation-Positive Advanced Solid Tumors

MA

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Navitoclax	ABT-263, A-855071.0, Bcl-2 Family Protein Inhibitor ABT-263	Bcl-2, Bcl-XL, and Bcl-w inhibitor	Clinical Trials
Trametinib	Mekinist, MEK Inhibitor GSK1120212, JTP-74057, GSK1120212, TMT212	MEK1/2 inhibitor	Approved in Other Cancers

II

Advanced solid tumors with NTRK1/2/3, ROS1, or ALK rearrangements

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients With Locally Advanced or Metastatic Solid Tumors That Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

TX

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Entrectinib	RXDX-101, TrkA/B/C/ROS1/ALK tyrosine kinase inhibitor RXDX-101, Rozlytrek	ALK, TRK, ROS1 kinase inhibitor	Approved in Other Cancers

II

Ovarian expansion for CDKN2A loss or MUT or ERBB2/ERBB3 AMP, MUT or over-expression, or high TMB or Advanced solid tumors with molecular alterations in AKT1, ALK, ATM, ATR, BRAF, BRAFV600E/D/K/R, BRCA1/2, CDK4/6 AMP, CDK12, CDKN2A, CHEK2, CSF1R, FANCA, FGFR1/2/3, FLT3, KIT, MET, MRE11A, MLH1, MSH2, MSH6, mTOR, NBN, NRG1, NTRK1/2/3 AMP, PALB2, PDGFR, PDGFRB, PMS2, POLD1, POLE, RAF-1, RAD51C, RET, ROS1, TSC1/2, VEGFR, or with high MSI, high TMB, HRD+, or LOHhi

Targeted Agent and Profiling Utilization Registry (TAPUR) Study

AL, AZ, CA, CT, FL, GA, HI, IL, IN, ME, MI, NE, NH, NM, NY, NC, ND, OH, OR, PA, SC, SD, TN, TX, UT, VA, WA, WI

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Abemaciclib	Bemaciclib, LY2853219, CDK4/6 Dual Inhibitor LY2835219, Verzenio	CDK4/6 inhibitor	Approved in Other Cancers
Afatinib	BIBW 2992 MA2, Gilotrif, Afatinib dimaleate	EGFR, HER2, HER4 kinase inhibitor	Approved in Other Cancers
Atezolizumab	Tecentriq, Anti-PD-L1 Monoclonal Antibody MPDL3280A, MPDL3280A, RG7446	Blocks PD-L1 inhibition of T cells	Approved in Other Cancers
Crizotinib	c-met/HGFR tyrosine kinase inhibitor PF-02341066, PF-02341066, Xalkori	c-Met and ALK kinase inhibitor	Approved in Other Cancers
Entrectinib	RXDX-101, TrkA/B/C/ROS1/ALK tyrosine kinase inhibitor RXDX-101, Rozlytrek	ALK, TRK, ROS1 kinase inhibitor	Approved in Other Cancers
Ipilimumab	Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, Yervoy	Blocks CTLA-4 inhibition of T cells	Approved in Other Cancers
Larotrectinib	Trk inhibitor LOXO-101, LOXO-101, Vitrakvi	pan-Trk kinase inhibitor	Approved in Other Cancers
Nivolumab	BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo	Blocks PD-L1/2 inhibition of T cells	Approved in Other Cancers
Palbociclib	PD-0332991, PD0332991, Ibrance	CDK4/6 inhibitor	Approved in Other Cancers
Pembrolizumab	Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475	Blocks PD-L1/2 inhibition of T cells	Approved in Other Cancers
Pertuzumab	Perjeta, monoclonal antibody 2C4, rhuMAb2C4	HER2 dimerization inhibitor	Approved in Other Cancers
PHESGO	pertuzumab, trastuzumab, and hyaluronidase-zzxf	HER2 antagonist	Approved in Other Cancers
Regorafanib	BAY73-4506, multikinase inhibitor BAY 73-4506, Stivarga	Multi-targeted RTK inhibitor	Approved in Other Cancers
Sunitinib	Sutent, Sunitinib malate	VEGFR2, PDGFR-beta, c-Kit, and FLT3 kinase inhibit	Approved in Other Cancers
Talazoparib	MDV3800, BMN-673, Talazoparib Tosylate, Talzenna	PARP inhibitor	Approved in Other Cancers
Temsirolimus	Torisel, CCI-779	mTOR inhibitor	Approved in Other Cancers
Trastuzumab	Herceptin, Anti-erbB2 Monoclonal Antibody, HER2 Monoclonal Antibody	HER2 antagonist	Approved in Other Cancers
Tucatinib	Irbinitinib, ONT-380	HER2 kinase inhibitor	Approved in Other Cancers

II

Expansion for BRAF V600E or V600K (except low grade serous), or advanced LAG-3+ solid tumors with dMMR

Molecular Analysis for Therapy Choice (MATCH)

AL, AK, AZ, AR, CA, CO, CT, DE, DC, FL, GA, HI, ID, IL, IN, IA, KS, KY, LA, ME, MD, MA, MI, MN, MS, MO, MT, NE, NV, NH, NJ, NM, NY, NC, ND, OH, OK, OR, PA, RI, SC, SD, TN, TX, UT, VT, VA, WA, WV, WI, WY

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Dabrafenib	GSK-2118436A, BRAF inhibitor GSK2118436, GSK2118436, Tafinlar	BRAF kinase inhibitor	Approved in Other Cancers
Nivolumab	BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo	Blocks PD-L1/2 inhibition of T cells	Approved in Other Cancers
Relatlimab	BMS986016, Anti-LAG-3 monoclonal antibody BMS-986016, Anti-LAG-3 monoclonal antibody BMS-986016	Blocks LAG-3 inhibition of T cells	Clinical Trials
Trametinib	Mekinist, MEK Inhibitor GSK1120212, JTP-74057, GSK1120212, TMT212	MEK1/2 inhibitor	Approved in Other Cancers

II

Advanced solid tumors with high MSI or high TMB

A Clinical Trial of Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Subjects With Advanced Solid Tumors (KEYNOTE 158)

CA, FL, MA, NJ, TX

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Pembrolizumab	Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475	Blocks PD-L1/2 inhibition of T cells	Approved in Other Cancers

II

Partially platinum sensitive or resistant ovarian cancer (for combo w/ rucaparib patients have to be BRCA WT and have no prior PARP inhibitor)

A Phase II Study With a Safety lead-in of Nivolumab in Combination With Bevacizumab or in Combination With Bevacizumab and Rucaparib for the Treatment of Relapsed Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer

MA

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Bevacizumab	Avastin, anti-VEGF monoclonal antibody, immunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain	VEGF antagonist	Approved in Ovarian Cancer
Nivolumab	BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo	Blocks PD-L1/2 inhibition of T cells	Approved in Other Cancers
Rucaparib	AG-014699, PF 01367338, CO-338, Rubraca	PARP inhibitor	Approved in Ovarian Cancer

II

Granulosa cell ovarian cancer

A Phase I/II Trial of TRC102 (Methoxyamine HCl) in Combination With Temozolomide in Patients With Relapsed Solid Tumors and Lymphomas

MD

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Methoxyamine	TRC102	Base excision repair inhibitor	Clinical Trials
Temozolomide	Temodal, Temodar, Methazolastone	DNA damaging agent	Approved in Other Cancers

II

Platinum resistant, refractory or persistent ovarian cancer (no measurable disease outside the peritoneal cavity)

MC1365, A Randomized Phase II Trial of a Genetically Engineered NIS-Expressing Strain of Measles Virus Versus Investigator's Choice Chemotherapy for Patients With Platinum-Resistant Ovarian, Fallopian, or Peritoneal Cancer

AZ, FL, MN

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
MV-NIS	oncolytic measles virus encoding thyroidal sodium iodide symporter	Induces immune response and tumor cell lysis	Clinical Trials

II

Advanced solid tumors with HER2 amplification

A Phase 2 Trial of Ado-Trastuzumab Emtansine for Patients With HER2 Amplified or Mutant Cancers

NJ, NY

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Trastuzumab emtansine	trastuzumab-MCC-DM1 immunoconjugate, trastuzumab-MCC-DM1 antibody-drug conjugate, trastuzumab-MCC-DM1, trastuzumab-DM1, T-DM1, Kadcyla, ado trastuzumab emtansine	ADC: anti-HER2 + microtubule destabilizer (DM1)	Approved in Other Cancers

II

Advanced ovarian small cell cancer

DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors

AL, AK, AZ, AR, CA, CO, CT, DE, DC, FL, GA, HI, ID, IL, IN, IA, KS, KY, LA, ME, MD, MA, MI, MN, MS, MO, MT, NE, NV, NH, NJ, NM, NY, NC, ND, OH, OK, OR, PA, SC, SD, TN, TX, UT, VT, VA, WA, WV, WI, WY

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Ipilimumab	Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, Yervoy	Blocks CTLA-4 inhibition of T cells	Approved in Other Cancers
Nivolumab	BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo	Blocks PD-L1/2 inhibition of T cells	Approved in Other Cancers

II

Advanced solid tumors with lesion treatable with radiation therapy

Randomized Phase II Study of Checkpoint Blockade Immunotherapy Combined With Stereotactic Body Radiation Therapy in Advanced Metastatic Disease

CA

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Atezolizumab	Tecentriq, Anti-PD-L1 Monoclonal Antibody MPDL3280A, MPDL3280A, RG7446	Blocks PD-L1 inhibition of T cells	Approved in Other Cancers
Ipilimumab	Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, Yervoy	Blocks CTLA-4 inhibition of T cells	Approved in Other Cancers
Nivolumab	BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo	Blocks PD-L1/2 inhibition of T cells	Approved in Other Cancers
Pembrolizumab	Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475	Blocks PD-L1/2 inhibition of T cells	Approved in Other Cancers
Radiation Therapy	Irradiation, Radiotherapy

II

Platinum resistant or refractory clear cell ovarian cancer or mixed epithelial carcinoma with a clear cell component

Randomized Phase II Trial of Durvalumab (MEDI4736) and Tremelimumab Administered in Combination Versus Sequentially in Recurrent Platinum-Resistant Epithelial Ovarian Cancer

TX

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Durvalumab	Anti-B7H1 Monoclonal Antibody MEDI4736, MEDI4736, Imfinzi	Blocks PD-L1 inhibition of T cells	Approved in Other Cancers
Tremelimumab	anti-CTLA4 human monoclonal antibody CP-675,206, CP-675, CP-675,206, CP-675206, Ticilimumab	Blocks CTLA-4 inhibition of T cells	Clinical Trials

II

Platinum resistant or refractory ovarian cancer

P53MVA and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

CA

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
p53MVA	Modified Vaccinia Virus Ankara Vaccine Expressing p53, MVAp53	Immune response against p53 tumor antigen	Clinical Trials
Pembrolizumab	Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475	Blocks PD-L1/2 inhibition of T cells	Approved in Other Cancers

II

Advanced solid tumors with IDH1 or IDH2 mutations

A Phase 2 Study of the PARP Inhibitor Olaparib (AZD2281) in IDH1 and IDH2 Mutant Advanced Solid Tumors

CA, CT, FL, KS, MD, MA, MO, NH, NJ, NY, NC, OH, OK, PA, TN, TX, WI

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Olaparib	Lynparza, AZD2281	PARP inhibitor	Approved in Ovarian Cancer

II

Advanced solid tumors with CCND1/2/3 alterations or CDK4/6 amplifications

A Phase II Study of the CDK4/6 Inhibitor Abemaciclib in Patients With Solid Tumors Harboring Genetic Alterations in Genes Encoding D-type Cyclins or Amplification of CDK4 or CDK6

MA

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Abemaciclib	Bemaciclib, LY2853219, CDK4/6 Dual Inhibitor LY2835219, Verzenio	CDK4/6 inhibitor	Approved in Other Cancers

II

Recurrent or pe